NDAORALTABLET, EXTENDED RELEASE
Approved
Sep 2009
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
KAPVAY (clonidine hydrochloride) by Teva is clinical pharmacology clonidine stimulates alpha-adrenoreceptors in the brain stem. First approved in 2009.
Drug data last refreshed Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KAPVAY is a clonidine hydrochloride extended-release oral tablet approved in 2009 that stimulates alpha-adrenoreceptors in the brain stem to reduce sympathetic outflow and decrease blood pressure, peripheral resistance, heart rate, and renal vascular resistance. The drug has a rapid onset (30-60 minutes) with maximum effect within 2-4 hours. While approved for ocular redness, clonidine is a well-established antihypertensive agent with a complex pharmacology affecting multiple cardiovascular parameters.
$0.008BPart D
LOE ApproachingDeclining
Product is in late-stage lifecycle with minimal Part D spending ($8K in 2023), indicating a niche commercial footprint with limited field team scaling opportunities.
Mechanism of Action
CLINICAL PHARMACOLOGY Clonidine stimulates alpha-adrenoreceptors in the brain stem. This action results in reduced sympathetic outflow from the central nervous system and in decreases in peripheral resistance, renal vascular resistance, heart rate, and blood pressure. Clonidine hydrochloride…
Worked on KAPVAY at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.